Activity of eltrombopag in severe aplastic anemia | 合法藥品大搜索

治療ITP 與SAA 患者時，. 對於肝功能不全的患者必須使用較低起始劑量的eltrombopag，並密切進行監測( 請參見. 4.2 章節)。 肝臟代償失調( 併用干擾素時). 慢性C 型 ... Read More

由 P Scheinberg 著作 · 2018 · 被引用 43 次 — The next steps in development combined eltrombopag with the most active IST regimen in SAA, horse ATG ... Read More

2018年11月17日 — Eltrombopag is also FDA-approved for SAA patients who have had an insufficient response to immunosuppressive therapy, for patients with ... Read More

How eltrombopag is acting in SAA — The next steps in development combined eltrombopag with the most active IST regimen in SAA, horse ATG ... Read More

由 J JIA 著作 · 2019 · 被引用 1 次 — Eltrombopag is an oral thrombopoietin receptor agonist. In a recent study of newly diagnosed SAA patients, combined standard ... Read More

Promacta (eltrombopag) is the first-in-class treatment indicated for patients with severe aplastic anaemia (SAA) immunosuppressive therapy (IST) was proven ... Read More

由 B Drexler 著作 · 2021 — For many decades, the therapy of SAA primarily focused on the immune pathogenesis of the disease, treating patients with either intensive ... Read More

由 H Lesmana 著作 — The thrombopoietin receptor agonist eltrombopag has been recently approved for SAA patients 2 years and older. However, there are limited ... Read More

6月1日起，治療血小板低下藥品「返利凝膜衣錠」（eltrombopag）給付範圍擴增，慢性自發 ... 再生不良性貧血（SAA）在免疫抑制劑反應不佳時，目前係以幹細胞 ... Read More